• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

18.66 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
3 Bullish Biotech Stocks With Explosive Growth Trends
July 21, 2025
These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies 
Via MarketBeat
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday
June 16, 2025
Via Benzinga
US Stocks Likely To Rebound After Sharp Decline Amid Israel-Iran Conflict: S&P 500 Historically Moves Higher After Wars, Says Expert
June 16, 2025
U.S. stock futures were trading higher on Monday following Friday's sharp declines. Futures of benchmark indices were higher in premarket. 
Via Benzinga
Topics Stocks
Earnings Scheduled For May 12, 2025
May 12, 2025
Via Benzinga
A Look at UroGen Pharma's Upcoming Earnings Report
May 09, 2025
Via Benzinga
UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri
June 16, 2025
UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer. 
Via Stocktwits
Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week
June 13, 2025
UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase. 
Via Benzinga
Top movers in Friday's session
June 13, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer
June 13, 2025
FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained response outcomes. 
Via Benzinga
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday
June 13, 2025
Via Benzinga
UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20
June 13, 2025
The new price target of $30 implies a near 171% upside to the stock’s closing price of $11.08 on Thursday. 
Via Stocktwits
Here are the top movers in Thursday's session.
June 12, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Which stocks are moving on Friday?
June 06, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
May 25, 2025
Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102. 
Via Benzinga
This Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
May 22, 2025
Via Benzinga
What's Going On With UroGen Pharma Stock Wednesday?
May 21, 2025
UroGen shares traded lower Wednesday after the ODAC of the Food and Drug Administration voted against the benefit/risk of UGN-102 (mitomycin) for intravesical solution. 
Via Benzinga
UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled
May 21, 2025
The Food and Drug Administration is expected to conclude its review of UroGen’s UGN-102 application by June 13. 
Via Stocktwits
Topics Artificial Intelligence
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
May 16, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Top stock movements in today's session.
May 16, 2025
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
The market is filled with gapping stocks in Friday's session.
May 16, 2025
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
April 28, 2025
UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer. 
Via Benzinga
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
April 28, 2025
Via Benzinga
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
April 17, 2025
Via Benzinga
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
April 16, 2025
Via Benzinga
Earnings Scheduled For March 10, 2025
March 10, 2025
Via Benzinga
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
January 14, 2025
Via Benzinga
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session
January 10, 2025
Via Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024
August 13, 2024
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
June 27, 2024
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
June 18, 2024
Via Benzinga
< Previous 1 2 3 4 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap